Integrins in Cardiovascular Health and Disease: Molecular Mechanisms and Therapeutic Opportunities

被引:0
作者
Lawkowska, Karolina [1 ]
Bonowicz, Klaudia [1 ,2 ]
Jerka, Dominika [1 ]
Bai, Yidong [3 ]
Gagat, Maciej [1 ,2 ]
机构
[1] Nicolaus Copernicus Univ Torun, Coll Med Bydgoszcz, Dept Histol & Embryol, PL-85092 Bydgoszcz, Poland
[2] Mazovian Acad Plock, Coll Med, PL-09402 Plock, Poland
[3] Univ Texas Hlth San Antonio, Dept Cell Syst & Anat, San Antonio, TX 78229 USA
关键词
integrins; cardiovascular diseases; vascular endothelial cells; vascular smooth muscle cells; platelets; cardiac fibroblasts; cardiomyocytes; integrin antagonists and antibodies; nanotherapy; LYMPHATIC ENDOTHELIAL-CELLS; ADHESION RECEPTORS; STRUCTURAL BASIS; MATRIX ADHESION; INFLAMMATION; ANGIOGENESIS; ACTIVATION; BINDING; ALPHA-1-BETA-1; MODEL;
D O I
10.3390/biom15020233
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cardiovascular diseases, including atherosclerosis, hypertension, and heart failure, remain the leading cause of global mortality, with endothelial dysfunction and vascular remodeling as critical contributors. Integrins, as transmembrane adhesion proteins, are central regulators of cell adhesion, migration, and signaling, playing a pivotal role in maintaining vascular homeostasis and mediating pathological processes such as inflammation, angiogenesis, and extracellular matrix remodeling. This article comprehensively examines the role of integrins in the pathogenesis of cardiovascular diseases, focusing on their dysfunction in endothelial cells and interactions with inflammatory mediators, such as TNF-alpha. Molecular mechanisms of integrin action are discussed, including their involvement in mechanotransduction, leukocyte adhesion, and signaling pathways that regulate vascular integrity. The review also highlights experimental findings, such as the use of specific integrin-targeting plasmids and immunofluorescence to elucidate integrin functions under inflammatory conditions. Additionally, potential therapeutic strategies are explored, including the development of integrin inhibitors, monoclonal antibodies, and their application in regenerative medicine. These approaches aim not only to mitigate pathological vascular remodeling but also to promote tissue repair and angiogenesis. By bridging insights from molecular studies with their translational potential, this work underscores the promise of integrin-based therapies in advancing the management and treatment of cardiovascular diseases.
引用
收藏
页数:27
相关论文
共 177 条
  • [1] Cross-talk between integrins α1β1 and α2β1 in renal epithelial cells
    Abair, Tristin D.
    Sundaramoorthy, Munirathinam
    Chen, Dong
    Heino, Jyrki
    Ivaska, Johanna
    Hudson, Billy G.
    Sanders, Charles R.
    Pozzi, Ambra
    Zent, Roy
    [J]. EXPERIMENTAL CELL RESEARCH, 2008, 314 (19) : 3593 - 3604
  • [2] Aimo A., 2022, Eur. Heart J. Suppl, V24, psuac012.173, DOI [10.1093/eurheartj/suac012.173, DOI 10.1093/EURHEARTJ/SUAC012.173]
  • [3] Endothelial Cell Heterogeneity
    Aird, William C.
    [J]. COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2012, 2 (01):
  • [4] Integrin as a Molecular Target for Anti-cancer Approaches in Lung Cancer
    Aksorn, Nithikoon
    Chanvorachote, Pithi
    [J]. ANTICANCER RESEARCH, 2019, 39 (02) : 541 - 548
  • [5] Integrin-Dependent Cell-Matrix Adhesion in Endothelial Health and Disease
    Aman, Jurjan
    Margadant, Coert
    [J]. CIRCULATION RESEARCH, 2023, 132 (03) : 355 - 378
  • [6] ATN-161 Ameliorates Ischemia/Reperfusion-induced Oxidative Stress, Fibro-inflammation, Mitochondrial damage, and Apoptosis-mediated Tight Junction Disruption in bEnd.3 Cells
    Amruta, Narayanappa
    Bix, Gregory
    [J]. INFLAMMATION, 2021, 44 (06) : 2377 - 2394
  • [7] Structural and mechanical functions of integrins
    Anderson L.R.
    Owens T.W.
    Naylor M.J.
    [J]. Biophysical Reviews, 2014, 6 (2) : 203 - 213
  • [8] [Anonymous], 2012, Nat. Rev. Clin. Oncol, V9, P249, DOI [10.1038/nrclinonc.2012.52, DOI 10.1038/NRCLINONC.2012.52]
  • [9] [Anonymous], Integrin Receptor-An Overview|ScienceDirect Topics
  • [10] Differences among GP IIb/IIIa inhibitors: different clinical benefits in non-ST-segment elevation acute coronary syndrome percutaneous coronary intervention patients
    Antoniucci, David
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2007, 9 (0A) : A32 - A36